Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.270
-0.080 (-1.84%)
Apr 29, 2025, 4:00 PM EDT - Market closed
Company Description
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release.
Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD; CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children; and CTx-2103 (buspirone) for the treatment of anxiety.
Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Dec 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Shane Schaffer |
Contact Details
Address: 1901 West 47th Place Kansas City, Kansas 66205 United States | |
| Phone | 913 942 2300 |
| Website | cingulate.com |
Stock Details
| Ticker Symbol | CING |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001862150 |
| CUSIP Number | 17248W105 |
| ISIN Number | US17248W2044 |
| Employer ID | 86-3825535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, Chief Executive Officer and Chairman of the Board |
| Jennifer L. Callahan CPA | Senior Vice President, Chief Financial Officer and Secretary |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President and Chief Science Officer |
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive Vice President and Chief Medical Officer |
| Thomas Dalton | Vice President of Investor and Public Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 9, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 3, 2025 | 8-K | Current Report |
| Jan 24, 2025 | 8-K | Current Report |